Gemphire stops NAFLD pediatric trial of gemcabene after liver fat elevations

Gemphire Therapeutics Inc. (NASDAQ:GEMP) will terminate an open-label Phase IIa trial of gemcabene (CI-1027) to treat pediatric patients with non-alcoholic fatty liver disease (NAFLD) after the first three patients to complete the 12-week trial showed higher levels of liver fat

Read the full 408 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE